U.S. Professional Services Stock News

Skyward Specialty Insurance Group recently reported fourth-quarter 2025 results that exceeded analyst expectations on both earnings and revenue, alongside new executive employment agreements and a US$9,320 common stock purchase by CFO Taryn Leonie McHarg on February 27, 2026. The company also moved to refresh its governance with the nomination of veteran reinsurance leader Peter Hearn as an independent director, succeeding long-serving board member Jim Hays later this year. We’ll now examine...

Institutional Selling Puts Par Pacific in Focus Harbor Capital Advisors Inc. recently cut its position in Par Pacific Holdings (PARR) by 25.7% in the fourth quarter, a move that draws attention to how large institutions currently view the stock. See our latest analysis for Par Pacific Holdings. Par Pacific's recent 1-day share price return of 5.22% to US$64.89 comes after strong share price momentum, including a 30-day share price return of 32.78% and a 90-day share price return of 74.15%...

If you are wondering whether On Holding's current share price makes sense for the risk and growth on offer, the valuation story is where things get interesting. The stock last closed at US$33.03, with a 2.0% gain over 7 days, a 20.3% decline over 30 days, and returns of 29.6% decline year to date and 16.6% decline over 1 year, while the 3 year return stands at 12.4%. Recent market coverage has focused on how On Holding fits into the premium athletic and footwear space, with investors...

If you are wondering whether VICI Properties is attractively priced or not, the starting point is understanding what the current share price is really reflecting about its future. The stock recently closed at US$27.66, with returns of 3.9% over the last 7 days, a 6.8% decline over 30 days, a 1.7% decline year to date, and a 4.0% decline over 1 year. The 3 year and 5 year returns sit at 1.3% and 25.6% respectively. Recent headlines around VICI Properties have focused on its role as a...

Zenas BioPharma (ZBIO) has just raised fresh capital through a twin financing, completing a US$100 million follow on common stock offering at US$20 per share and a US$200 million 2.50% convertible notes issue due 2032. See our latest analysis for Zenas BioPharma. The fresh capital raise comes after a mixed stretch for the stock, with a 29.2% 90 day share price return contrasting with a 15.1% 1 month share price decline, while the 1 year total shareholder return of 178.3% points to strong...

In recent weeks, Viasat has drawn fresh attention after its leadership highlighted satellite and space network capabilities at the SATELLITE 2026 conference in Washington, alongside sector-wide enthusiasm for advanced satellite communications technologies. These developments coincide with heightened interest in secure, resilient connectivity and direct-to-device satellite services, underscoring how Viasat’s technology roadmap is increasingly aligned with evolving global communications...

In late March 2026, brands including Opopop, FHI Heat and Zep announced nationwide product launches at Walmart, while Sam’s Club revealed its first membership fee increase in four years and Walmart confirmed selected U.S. fulfillment center closures amid a broader automation push. These moves highlight Walmart’s effort to deepen higher-margin revenue through memberships and advertising-supported product discovery, while reshaping its supply chain cost base with increased automation. Next,...

In recent weeks, Dell Technologies has rolled out a revamped AI-ready commercial hardware portfolio and enhanced cyber-resilience offerings, while also securing a multi-year private cloud infrastructure agreement with London Stock Exchange Group. Together with disclosures about a very large AI-optimized server order backlog and thousands of AI Factory deployments, these developments highlight Dell’s deepening role as a core infrastructure partner for enterprise AI workloads. We’ll now...

Why Adaptive Biotechnologies Is On Investors’ Radar Adaptive Biotechnologies (ADPT) has drawn attention after a strong 1 year total return of 98.26%, prompting investors to reassess how its immune medicine platform, revenue mix, and ongoing net losses fit into their portfolios. See our latest analysis for Adaptive Biotechnologies. The recent 19.34% 7-day share price return, against a softer 90-day share price return of an 8.41% decline, suggests short-term momentum has picked up even as...

Why Veeva Systems (VEEV) is on investors’ radar right now Veeva Systems (VEEV) is drawing attention after a mixed stretch for the stock, with gains over the past week and day contrasting with weaker returns over the past month and past 3 months. See our latest analysis for Veeva Systems. At a share price of $173.98, Veeva’s short term momentum has cooled, with a 30 day share price return of 11% and a 90 day share price return of 21.39% contributing to a 1 year total shareholder return of...

Johnson & Johnson (JNJ) is in focus after two recent autoimmune updates, positive 52 week Phase 3 results for oral psoriasis drug ICOTYDE, and a US$500 million R&D partnership with Royalty Pharma on antibody therapy JNJ-4804. See our latest analysis for Johnson & Johnson. Against this backdrop of autoimmune pipeline news, Johnson & Johnson’s share price has climbed 19.0% over the past 90 days and 17.2% year to date, contributing to a 63.0% total shareholder return over twelve months that...

What recent performance says about TowneBank TowneBank (TOWN) has drawn attention after a period of steady, mixed returns, with the share price roughly flat over the past 3 months and showing gains over the past year and year to date. See our latest analysis for TowneBank. The recent 7 day share price return of 2.23% and 1 year total shareholder return of 14.30% suggest momentum has been building over the past year, even though the latest 1 day move was slightly negative. If you are...

Framing Halliburton after recent performance Halliburton (HAL) has drawn fresh attention after a mix of short term pullback and stronger recent gains, with the stock showing a 0.4% move over the past day and a negative 5.6% return over the past week. See our latest analysis for Halliburton. While the recent 5.6% one week share price pullback stands out, the 30 day share price return of 12.1% and year to date share price return of 28.9%, alongside a 1 year total shareholder return of 96.3%,...

Upwork (NasdaqGS:UPWK) is rolling out new AI driven features on its freelance platform, including its assistant Uma and expanded workforce management tools. The company is extending these capabilities across its marketplace to support both businesses and freelancers who rely on remote and project based work. The updates are part of an ongoing effort to integrate AI into talent discovery, project scoping, and ongoing engagement on the platform. For investors tracking online talent platforms,...

Trevi Therapeutics recently completed its end-of-phase 2 meeting with the FDA, securing regulatory alignment on the development plan for Haduvio, its oral extended-release nalbuphine, in idiopathic pulmonary fibrosis-related chronic cough. This alignment, including agreement on using objective cough monitoring as the primary endpoint, clarifies Trevi’s clinical path and reduces a key source of regulatory uncertainty around Haduvio’s program. We’ll now explore how this FDA alignment on...

In March 2026, Worthington Enterprises, Inc. reported higher year-over-year third-quarter and nine-month sales and net income, continued its share repurchases, and its Board declared a US$0.19 per-share quarterly dividend payable on June 29, 2026. Together, the earnings growth, ongoing buybacks that have retired more than two-fifths of shares since 2014, and the uninterrupted dividend record since 1968 highlight the company’s long-running focus on returning cash to shareholders. Next, we’ll...

Why Xenon Pharmaceuticals (XENE) Is On Investors’ Radar Xenon Pharmaceuticals (XENE) has been drawing attention after a strong run, with the stock up about 36% over the past month and around 36% in the past 3 months. See our latest analysis for Xenon Pharmaceuticals. That recent surge comes on top of a 27.78% year to date share price return and a 93.37% total shareholder return over the past year, suggesting momentum has been building rather than fading. If Xenon’s move has you looking at...

Kingsoft Cloud Holdings recently reported its fourth-quarter and full-year 2025 results, showing higher revenue and smaller net losses, while also announcing the resignation of long-time chairman Lei Jun and the appointment of Zou Tao as the new chairman alongside additional board changes. At the same time, the company moved to modernize its governance by proposing amendments to its Articles of Association to enable virtual shareholder meetings and better align with Hong Kong Listing Rules,...

Context for Bank of Hawaii Stock Bank of Hawaii (BOH) is back on investors’ radar after recent share price moves, with the stock showing mixed short term returns and stronger figures over the past year and past 3 months. See our latest analysis for Bank of Hawaii. At the current share price of $74.79, Bank of Hawaii combines a 9.3% year to date share price return with a 26.6% 1 year total shareholder return and a 70.2% 3 year total shareholder return, hinting that positive momentum has been...

ONEOK (OKE) is back in focus as investors weigh recent price swings, an upcoming first quarter earnings release in late April, and fresh analyst attention tied to changing global energy conditions. See our latest analysis for ONEOK. Recent swings, including a 3.86% intraday drop on 1 April and other sessions where the share price declined even as the broader market advanced, sit against a broader backdrop where the 90 day share price return of 19.89% and 1 year total shareholder return of...

KB Home (KBH) stock came under pressure after first quarter earnings and cautious revenue guidance, as softer net orders, lower deliveries and thinner margins met already weak sentiment around higher mortgage rates. See our latest analysis for KB Home. The 12.0% 1 month share price decline and 10.9% year to date share price decline suggest momentum has cooled, even though the 3 year total shareholder return of 38.5% still reflects a materially stronger longer term outcome. If earnings...

Comcast (CMCSA) is back in focus after outlining heavier broadband spending, a simpler internet pricing structure, and a new AI edge-computing partnership with NVIDIA, all shaping expectations for future monetization and near-term profitability pressure. See our latest analysis for Comcast. Despite a steady stream of broadband build outs and the new NVIDIA partnership, Comcast’s recent share price performance has been weak. The company has reported a 30 day share price return of 12.47% and a...

In early April 2026, Ferguson Enterprises drew fresh analyst support as research firms highlighted its robust fiscal guidance and growing exposure to non-residential construction, especially for data center-related projects. This renewed focus on Ferguson’s role in supplying critical infrastructure for data centers underscores how shifting technology needs are influencing demand in its core end markets. Next, we’ll examine how this increased emphasis on data center-driven non-residential...

Motorola Solutions (MSI) stepped into ISC West 2026 with its expanded AI-driven security platform as a showcase for how video, access control and software can work together as a real-time intelligence layer. See our latest analysis for Motorola Solutions. The recent ISC West 2026 platform expansion, together with acquisitions in Canadian land mobile radio and cloud recording, has come alongside a 14.7% 90 day share price return and a 143.83% five year total shareholder return, suggesting...